{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-112184","form_type":"8-K","ticker":"APUS","cik":"0001894525","company_name":"Apimeds Pharmaceuticals US, Inc.","filed_at":"2025-11-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.006717+00:00","generated_at":"2026-05-16T18:52:57.022763+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Apimeds boosts CEO salary to $500K and adds 24-month severance with equity vesting","bullets":["CEO Erik Emerson's annual base salary increased to $500,000, effective Nov 13, 2025.","If terminated without cause, Emerson gets 24 months salary/benefits plus immediate vesting of all unvested equity.","On termination for cause or voluntary quit without good reason, unvested equity forfeited automatically.","Amendment modifies the original Sept 21, 2023 employment agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-112184","json":"https://secwatch.observer/filing/0001213900-25-112184.json","markdown":"https://secwatch.observer/filing/0001213900-25-112184.md","text":"https://secwatch.observer/filing/0001213900-25-112184.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1894525/000121390025112184/0001213900-25-112184-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1894525/000121390025112184/ea0266166-8k_apimeds.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T18:52:57.022763+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}